Download PDFPDF

OpenPrescribing: normalised data and software tool to research trends in English NHS primary care prescribing 1998–2016
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Tool now includes 2017 data (update from the author)

    In this paper we described how we created an open-data exploration tool at by compiling and normalising England’s national prescribing data for 1998–2016 [1], with the aim of facilitating the exploration of long-term prescribing trends. We have now updated this tool to include the data for 2017, which was released in March. Anyone can access our data tool at

    The Office for National Statistics does not release official mid-year population estimates for the previous year until June. Until then, for 2017 we have used their projected England population figure [2] and will update the tool again with the final figure when available.

    Our tool shows that the total number of items prescribed in 2017 increased marginally on the previous year, with a slight reduction in overall cost, across the core chapters (1-15) of the British National Formulary (BNF). The sections with the greatest increase in cost were Drugs used in Diabetes (+£7.8k inflation-corrected cost per 1,000 population) and Anticoagulants and Protamine (+£6.5k), whereas Lipid-Regulating Drugs decreased by £5.2k. Antidepressant Drugs have seen the largest increase in prescribing (+464 items per 1,000 population). Users can use the tool to explore the data down to the level of individual brands for each chemical substance.

    A further improvement to the tool was also carried out recently, to smooth out sudden increases and decreases in prescribi...

    Show More
    Conflict of Interest:
    None declared.